Advagene Biopharma Co., Ltd.

TPEX:6709 Stock Report

Market Cap: NT$1.4b

Advagene Biopharma Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Yu-Shen Hsu

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.8yrs
CEO ownershipn/a
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Advagene Biopharma (GTSM:6709) Is In A Strong Position To Grow Its Business

Mar 24
Advagene Biopharma (GTSM:6709) Is In A Strong Position To Grow Its Business

Here's Why We're Not At All Concerned With Advagene Biopharma's (GTSM:6709) Cash Burn Situation

Dec 10
Here's Why We're Not At All Concerned With Advagene Biopharma's (GTSM:6709) Cash Burn Situation

CEO

Yu-Shen Hsu

1.8yrs

Tenure

Mr. Yu-Shen Hsu serves as Chairman of Advagene biopharma Co.,Ltd since August 2022 and has been its Acting President, General Manager and Director.

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.